FierceBiotech

AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD

AstraZeneca today announced positive top-line results from the Phase III PINNACLE programme, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of ...
FierceBiotech

Pearl Therapeutics' Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Pat

Pearl Therapeutics' Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD - Additional Details of Primary and Secondary Endpoints ...
Medindia

Pearl Therapeutics' Data for its Combination Bronchodilator Product, PT003, Support the Potential for Improvement in the Treatment of Patients with COPD

REDWOOD CITY, Calif., May 18 Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory ...
Medindia

Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD

- New Clinical and Product Development Data Presented at American Thoracic Society (ATS) International Conference and Respiratory Drug Delivery (RDD) Meeting - REDWOOD CITY, Calif., May 14, 2011 ...